CTI BioPharma's (CTIC) Pacritinib Placed on Full Clinical Hold; NDA Withdrawn

WallachBeth Capital Downgrades CTI BioPharma (CTIC) to Sell, PT $0

WallachBeth Capital downgraded CTI BioPharma (NASDAQ: CTIC) from Hold to Sell with a price target of $0.00.

For an analyst ratings summary and ratings history on CTI BioPharma click here. For more ratings news on CTI BioPharma click here.

Shares of CTI BioPharma closed at $0.50 yesterday.

Piper Jaffray Downgrades CTI BioPharma (CTIC) to Neutral

Piper Jaffray downgraded CTI BioPharma (NASDAQ: CTIC) from Overweight to Neutral with a price target of $0.75 (from $4.00) after the FDA announced it has placed pacritinib (pac) on a full clinical hold following observations of decreased interim survival in the PERSIST-2 pac arm, following a... More

FDA Places Partial Clinical Hold on CTI BioPharma's (CTIC) Pacritinib IND

CTI BioPharma Corp. (CTI BioPharma) (Nasdaq: CTIC) announced that the Company received written communication from the U.S. Food and Drug Administration (FDA) on February 4, 2016, that the FDA has placed a partial clinical hold on the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. This clinical hold impacts part of the clinical work currently being conducted under the IND and will also affect planned clinical trials.

Under the partial clinical hold, clinical investigators may not enroll new patients or start pacritinib as initial or crossover treatment, and... More